Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy
Taselisib is investigated as a new oral treatment for ER+, HER2- type of breast cancer. It is being investigated as a medicine to work on a pathway regulating cell growth and cell survival. If taken in combination with an intramuscular injection of fulvestrant, which stops the effect of hormones altering the breast cells, taselisib has the potential to prolong survival. If licenced, this combination of treatments will offer an additional therapy option for those who have already had hormonal therapy but their cancer has relapsed.